FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
|Videos|June 14, 2021
A Welcome Addition to the Child and Adolescent ADHD Armamentarium
Author(s)Ann Childress, MD
This new medication is a huge leap forward for treating attention-deficit/hyperactivity disorder.
Advertisement
Ann Childress, MD, talks about
Dr Childress is a practicing psychiatrist with a subspecialty in child and adolescent psychiatry, clinical researcher, and president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas.
Advertisement
Related to this article
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5